Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 20Recruiting 7Unknown 6Terminated 5Not yet recruiting 3Active not recruiting 3Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Acetylcysteine × Clear all
NCT03982537 2022-12-19

Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome

Wake Forest University Health Sciences

Phase 2 Withdrawn
Head & Neck

Head and Neck Neoplasms

NCT01138137 2017-04-21

N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer

OHSU Knight Cancer Institute

Phase 1 Withdrawn
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡